COLLABORATIONS AND ALLIANCES (Detail Textuals) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenues		$ 1,227,000
Daiichi Sankyo Tivantinib Agreement | Phase 3 collaboration costs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cumulative share of phase 3 collaboration costs	$ 107,700,000
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received	67,700,000
Net revenues	0	700,000
Kyowa Hakko Kirin Licensing Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenues	$ 0	$ 500,000